Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are highly prevalent gastrointestinal disorders that can have a major impact on patients’ quality of life, work productivity and healthcare costs.
This program supports pharmacists in optimizing their management of chronic idiopathic constipation (CIC), constipation-predominant IBS (IBS-C), and diarrhea-predominant IBS (IBS-D) within pharmacy practice. Using case studies, the program will review recommendations supported by the Canadian Association of Gastroenterology (CAG). It will also encourage pharmacists to recognize red flags and to also recognize the
need for timely escalation of treatment in people who continue to have symptoms despite the use of OTC medications.
This program has received an educational grant or in-kind support from Allergan.